 So, we're pleased that you selected our paper called, Campypecan Targets Warner Protein, Mechanisms and Relevance in Clinical Breast Cancer for Your Cover. And we, the first author is Raghavendra Shyamana. And it's a collaboration between our group and the group of Madhusudan in the UK. In the UK, and we've worked together on this project for a while, we're trying to connect the clinical perspectives of breast cancer with the expression patterns and function of the Warner protein. And in my lab, we've worked with Warner protein for a long period of time. It is defective in a premature aging disease called Warner syndrome. By premature or any accelerated aging, it's a condition where the patients appear much older than they actually are. And it's actually an interesting, amazing number of features that you see in Warner syndrome that resemble what you see much later in the normal aging process. So Warner's syndrome remarkably reflects normal aging but just at a much earlier stage. This happens when the patients are in their 20s and then they fast become very aged. So we have been interested in studying Warner protein because we think that this condition can give us insight into what happens in normal aging. And we have together with many other investigators found that it is, Warner's protein is very important in what we call genomic stability. So it's maintenance of the DNA. The DNA is very susceptible to damage coming from everywhere of the environment and from the cell metabolism. And this damage leads to a lot of problems that in fact could very well underlie much of what we see in the aging process. So Warner's role is to help prevent, but this help get this damaged repair and the DNA very efficiently. And if Warner's protein is not there, you don't, you have a lot of this damage accumulating and a lot of problems that burn the cells. So for a long time, we've studied this process, the function of Warner's protein and its role in this DNA maintenance, DNA repair process. And we find that it interacts with other proteins. It has important critical functions in the DNA repair. Now at the same time, Warner's protein has been known for a while to be a tumor suppressor protein meaning that if you don't have Warner's protein, you're more susceptible to cancers. We know that from humans, we know that from other studies that Warner's has a protective function against cancers. So we have then been working with some colleagues in the United Kingdom who have assembled one of the biggest clinical studies on breast cancer in the world. And they have been interested in how we put better understand why some breast cancers become particularly malignant and others not so much. So they're studying how these proteins that are involved in DNA maintenance, how they're expressed, how they function in clinical breast cancer and in the very malignant tumors. So we first found with that group that the expression patterns of Warner relate to the breast cancer development. So you can correlate how much Warner functioned the risk to the degree of malignancy in the tumor. And then in addition, so we described this in this paper for the first time, there's such a connection between Warner levels, Warner protein and the breast cancer development. And the breast cancers were analyzed for very many details that all describe the degree of malignancy in the breast cancers. And there are breast cancers that are hormone sensitive and not hormone sensitive and many, many aspects. So then we found in our cellular work in the laboratory that Warner protein is degraded in cells when they're treated with campythegon and campythegon is a anti-cancer drug that's used in some form of cancers. It's also called a topoisomalase one inhibitor. And so this was a unique thing that Warner particularly gets degraded. And so we connected this cellular finding with the clinical findings. And we in addition in this paper have looked at a battery of cell lines that are found in the National Cancer Institute where they look at the cell lines and the sensitivity of cell lines to drugs. And we looked at cell lines and their sensitivity to campythegon and their expression of Warner. And kind of putting it all together we think that there was an interesting connection here that when we have malignant cancers we could potentially treat them with campythegon and then degrade Warner's protein as one way of making cells less able to repair DNA damage and therefore treatment of cells with drugs that damage DNA would be more effective under these conditions. And so in breast cancer at this point campythegons are not currently used but it's in the working. There are plans to use campythegon in the future. And we may have here found a marker for whether individual patients would be sensitive to such treatment by looking at the degradation of Warner protein in the cells. So it does represents a step and further understanding of this Warner protein and how it functions in protection against aging and cancer. And it also represents a possible step towards developing a bio marker for individual treatment of breast cancer. Our hope is that that can be further explored.